Catalyst Pharmaceuticals logo
Catalyst Pharmaceuticals CPRX
$ 24.53 -0.2%

Quarterly report 2025-Q3
added 11-05-2025

report update icon

Catalyst Pharmaceuticals Financial Statements 2011-2026 | CPRX

Annual Financial Statements Catalyst Pharmaceuticals

2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

2.44 B 1.56 B 1.48 B 595 M 377 M 431 M 254 M 299 M 90.3 M 150 M 234 M 90.5 M 16.2 M 23.7 M

Shares

118 M 106 M 103 M 103 M 104 M 103 M 103 M 85.8 M 82.9 M 80.9 M 64.1 M 45.5 M 30 M 21.7 M

Historical Prices

20.6 14.7 14.3 5.76 3.64 4.11 2.52 3.39 1.12 1.86 3.65 1.95 0.52 1.08

Net Income

164 M 71.4 M 83.1 M 39.5 M 75 M 31.9 M -34 M -18.4 M -18.1 M -20.2 M -15.5 M -12.2 M -4.08 M -6.39 M

Revenue

492 M 398 M 214 M 141 M 119 M 102 M 500 K - - - - - - -

Cost of Revenue

68.8 M 52 M 34.4 M 21.9 M 17 M 14.8 M - - - - - - - -

Gross Profit

- - - - - 87.5 M - - - - - - - -

Operating Income

195 M 86.8 M 102 M 52.4 M 41.3 M 31.8 M -35.3 M -18.7 M -19.3 M -20.4 M -14.6 M -10.3 M -5.22 M -6.08 M

Interest Expense

21.1 M 7.7 M 2.88 M 282 K 587 K 1.59 M 1.29 M 454 K 322 K 100 K 76.2 K 47.4 K 15 K -

EBITDA

196 M 87.1 M 102 M 52.6 M 41.4 M 32.1 M -35.3 M -18.6 M -19.2 M -20.4 M -14.6 M -10.3 M -5.21 M -6.04 M

Operating Expenses

190 M 227 M 76.9 M - - 55.7 M 35.8 M 18.7 M 19.3 M 20.4 M 14.6 M 10.3 M 5.22 M 6.08 M

General and Administrative Expenses

59 M 42.2 M 26 M 49.6 M 44.2 M 36.9 M 15.9 M 7.3 M 7.91 M 8.6 M 4.47 M 2.21 M 2.56 M 2.7 M

All numbers in USD currency

Quarterly Income Statement Catalyst Pharmaceuticals

2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

123 M 122 M 121 M 121 M 119 M 118 M 117 M 107 M 107 M 106 M 106 M 105 M 103 M 103 M 103 M 103 M 103 M 103 M 104 M 104 M 104 M 103 M 103 M 103 M 103 M 103 M 103 M 103 M 103 M 103 M 103 M 103 M 84.8 M 83.9 M 83 M 83 M 82.9 M 82.9 M 82.9 M 82.9 M 82.5 M 82 M 76 M 69.1 M 67.2 M 66.2 M 54.1 M 54.1 M 44.7 M 41.4 M 41.4 M 41.4 M 32.1 M 26.9 M 24.7 M 24.7 M 21.7 M 21.7 M 24.7 M

Net Income

52.8 M 52.1 M 56.7 M - 43.9 M 40.8 M 23.3 M - -30.8 M 37.8 M 29.6 M - 22.7 M 21.6 M 13.2 M - 10.3 M 12.2 M 7.66 M - 43.3 M 9.78 M 10.4 M 7.93 M 13.6 M 11 M -645 K -14.5 M -7.84 M -5.97 M -5.7 M -5.39 M -4.18 M -3.88 M -4.97 M -4.16 M -3.95 M -4.57 M -5.39 M -5.82 M -4.45 M -4.56 M -5.41 M -3.49 M -5.01 M -3.2 M -3.81 M -1.35 M -5.91 M -3.14 M -1.74 M -76.6 K -2.62 M -289 K -1.09 M -2.35 M -1.13 M -1.39 M -1.52 M

Revenue

148 M 147 M 141 M - 129 M 123 M 98.5 M - 103 M 99.6 M 85.4 M - 57.2 M 53.1 M 43.1 M - 36 M 36.4 M 30.2 M - 29.3 M 29.6 M 29.1 M 30.1 M 30.9 M 28.8 M 12.4 M 500 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Cost of Revenue

22.7 M 20.6 M 17.9 M - 19.3 M 15.4 M 12.5 M - 14.2 M 12 M 9.95 M - 9.66 M 7.64 M 5.89 M - 5.31 M 4.54 M 4.68 M - 3.88 M 4.14 M 4.15 M - 4.39 M 4.26 M 1.71 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Income

66.3 M 66.3 M 63.4 M - 50.9 M 54.2 M 27.1 M - -37.2 M 46.7 M 35.6 M - 25.1 M 28.6 M 17.4 M - 14 M 15.8 M 9.8 M - 11.7 M 10.3 M 10.7 M 8.01 M 13.8 M 11 M -988 K -14.8 M -8.18 M -6.34 M -5.93 M -5.51 M -4.31 M -4.18 M -4.68 M -4.31 M -3.91 M -4.81 M -6.24 M -6.19 M -5.02 M -4.9 M -4.29 M -3.98 M -4.11 M -2.99 M -3.51 M -2.71 M -3.25 M -2.65 M -1.71 M -1.51 M -1.28 M -1.07 M -1.36 M -2.03 M -1.13 M -1.4 M -1.52 M

Interest Expense

4.77 M 3 M 7.92 M - 6.3 M 1.54 M 1.96 M - -833 K 1.81 M 1.7 M - 905 K -324 K 93 K - 68 K 62 K 81 K - 33 K 111 K 336 K - 393 K 450 K 343 K - 344 K 371 K 234 K - 129 K 91 K 110 K - 67 K 92.8 K 118 K - 46.7 K 4.87 K 61.9 K - 5.92 K 15.7 K 32.8 K - - - - - - - - - - - -

EBITDA

- - 63.5 M - - - 27.2 M - - - 35.7 M - 25.2 M 28.6 M 17.4 M - 14.2 M 16 M 9.9 M - 11.8 M 10.3 M 10.7 M 8.01 M 13.9 M 11 M -974 K -14.8 M -8.17 M -6.33 M -5.93 M -5.51 M -4.29 M -4.17 M -4.67 M -4.31 M -3.9 M -4.81 M -6.22 M -6.19 M -5.01 M -4.89 M -4.28 M -3.98 M -4.1 M -2.98 M -3.5 M -2.71 M -3.24 M -2.65 M -1.7 M -1.51 M -1.28 M -1.06 M -1.36 M -2.03 M -1.12 M -1.38 M -1.51 M

Operating Expenses

50.1 M 50.3 M 50.8 M - 49.2 M 43.7 M 49.5 M - - - - - - - - - - - - - - - - - - 17.9 M 13.4 M - 8.18 M 6.34 M 5.93 M - 4.31 M 4.18 M 4.68 M - 3.91 M 4.81 M 6.24 M - 5.02 M 4.9 M 4.29 M - 4.11 M 2.99 M 3.51 M - 3.25 M 2.65 M 1.71 M - 1.28 M 1.07 M 1.36 M - 1.13 M 1.4 M 1.52 M

General and Administrative Expenses

15 M 14.8 M 14.8 M - 14.9 M 12.6 M 19.9 M - 33.6 M 28.4 M 29.7 M - 13.6 M 12.9 M 16.4 M - 12.2 M 11.5 M 12.7 M - 9.98 M 10.8 M 10.1 M - 8.07 M 8.99 M 8.42 M - 3.64 M 2.63 M 2.67 M - 1.6 M 1.73 M 1.87 M - 1.42 M 2.31 M 2.69 M - 1.97 M 2.32 M 1.94 M - 1.22 M 891 K 760 K - 441 K 521 K 613 K - 629 K 535 K 637 K - 517 K 492 K 615 K

All numbers in USD currency

Financial statements are the primary tool companies use to inform stakeholders about their financial position, performance, and changes in capital structure. It is a kind of "business language" understood by investors, creditors, tax authorities, and other participants in the economic environment.

Main types of financial statements Catalyst Pharmaceuticals CPRX
  1. Income Statement
    Shows income, expenses, and resulting profit or loss over a specific period. Helps assess business profitability.
  2. Balance Sheet
    Reflects a company’s assets, liabilities, and equity as of a specific date. It’s a snapshot of what the company owns and owes.
    Assets — everything the company owns (cash, equipment, buildings, accounts receivable, etc.).
    Liabilities — debts and other external sources of financing.
    Equity — owners' capital and retained earnings.
  3. Cash Flow Statement
    Reveals how the company earns and spends money in three areas: operating, investing, and financing activities.
International reporting standards
  • IFRS — International Financial Reporting Standards, applicable to public and multinational companies.
  • GAAP — Generally Accepted Accounting Principles used in the United States.
  • RAS — Russian Accounting Standards, used domestically in Russia.

Financial reporting Catalyst Pharmaceuticals plays a crucial role for investors as it serves as an objective source of information about a company's current state. Based on the reports, one can determine whether a company is growing, stagnating, or losing market share. This allows investors to identify both promising and problematic assets in a timely manner.

In addition, financial data provides a basis for forecasting future returns. Historical trends in revenue, profit, and cash flow help evaluate potential dividends, the likelihood of stock price growth, and overall investment risk.

Transparent and accurate reporting is also an indicator of a company’s maturity and managerial responsibility. Such openness builds investor confidence and simplifies investment decision-making, especially when comparing multiple companies.

Finally, financial statements enable high-quality comparative analysis. They allow companies to be evaluated against each other in terms of profitability, debt levels, margins, and other key metrics — which is particularly important when choosing the best investment options within an industry or market segment.

Financial statements of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
Acorda Therapeutics Acorda Therapeutics
ACOR
- -24.86 % $ 820 K usaUSA
Acasti Pharma Acasti Pharma
ACST
- 4.01 % $ 150 M canadaCanada
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
Adagene Adagene
ADAG
$ 2.82 -3.07 % $ 159 M chinaChina
ARCA biopharma ARCA biopharma
ABIO
- 1052.0 % $ 415 M usaUSA
Albireo Pharma Albireo Pharma
ALBO
- -0.23 % $ 916 M usaUSA
ANI Pharmaceuticals ANI Pharmaceuticals
ANIP
$ 81.54 -0.56 % $ 1.58 B usaUSA
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
- - $ 40.3 B usaUSA
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
- -1.52 % $ 24.7 M usaUSA
Aytu BioScience Aytu BioScience
AYTU
$ 2.57 -0.39 % $ 16.1 M usaUSA
Alterity Therapeutics Limited Alterity Therapeutics Limited
ATHE
$ 3.16 -3.07 % $ 7.6 B australiaAustralia
Akero Therapeutics Akero Therapeutics
AKRO
- - $ 3.67 B usaUSA
Allena Pharmaceuticals Allena Pharmaceuticals
ALNA
- 3.16 % $ 1.9 M usaUSA
AVROBIO AVROBIO
AVRO
- 1083.1 % $ 745 M usaUSA
Aptose Biosciences Aptose Biosciences
APTO
- -45.71 % $ 1.2 M canadaCanada
Aravive Aravive
ARAV
- -13.39 % $ 1.45 M usaUSA
Brickell Biotech Brickell Biotech
BBI
- -5.38 % $ 6.06 M usaUSA
Beam Therapeutics Beam Therapeutics
BEAM
$ 28.34 -3.26 % $ 2.33 B usaUSA
Applied Molecular Transport Applied Molecular Transport
AMTI
- - $ 10.1 M usaUSA
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
- - - russiaRussia
Ascendis Pharma A/S Ascendis Pharma A/S
ASND
$ 224.83 0.39 % $ 5 B danmarkDanmark
Athira Pharma Athira Pharma
ATHA
- - $ 269 M usaUSA
Atreca Atreca
BCEL
- -11.76 % $ 5.79 M usaUSA
Biogen Biogen
BIIB
$ 176.86 0.41 % $ 25.8 B usaUSA
BioNTech SE BioNTech SE
BNTX
$ 116.66 -0.09 % $ 27.2 B germanyGermany
Arrowhead Pharmaceuticals Arrowhead Pharmaceuticals
ARWR
$ 70.31 1.72 % $ 9.4 B usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
- 5.93 % $ 314 M canadaCanada
AgeX Therapeutics AgeX Therapeutics
AGE
- -10.17 % $ 12.2 K usaUSA
Burford Capital Limited Burford Capital Limited
BUR
$ 9.55 -1.09 % $ 1.51 B britainBritain
Akouos Akouos
AKUS
- 0.23 % $ 488 M usaUSA
Bellicum Pharmaceuticals Bellicum Pharmaceuticals
BLCM
- -9.72 % $ 5.89 M usaUSA
Adaptimmune Therapeutics plc Adaptimmune Therapeutics plc
ADAP
- -15.15 % $ 60.3 M britainBritain
Berkeley Lights Berkeley Lights
BLI
- -7.31 % $ 87 M usaUSA
Can-Fite BioPharma Ltd. Can-Fite BioPharma Ltd.
CANF
$ 4.15 1.22 % $ 9.03 B israelIsrael
Amneal Pharmaceuticals Amneal Pharmaceuticals
AMRX
$ 13.88 -1.63 % $ 4.29 B usaUSA
Catalyst Biosciences Catalyst Biosciences
CBIO
$ 10.01 -1.38 % $ 659 M usaUSA
AIkido Pharma AIkido Pharma
AIKI
- 1.93 % $ 17.4 M usaUSA
Bellerophon Therapeutics Bellerophon Therapeutics
BLPH
- -74.18 % $ 955 K usaUSA
CureVac N.V. CureVac N.V.
CVAC
- - $ 867 M germanyGermany
Acer Therapeutics Acer Therapeutics
ACER
- 2.71 % $ 14 M usaUSA
Alpine Immune Sciences Alpine Immune Sciences
ALPN
- - $ 2.17 B usaUSA
AlloVir AlloVir
ALVR
- 4.14 % $ 49.1 M usaUSA
Ampio Pharmaceuticals Ampio Pharmaceuticals
AMPE
- -11.43 % $ 502 K usaUSA
Baudax Bio Baudax Bio
BXRX
- 0.59 % $ 63 K usaUSA
Calithera Biosciences Calithera Biosciences
CALA
- -10.95 % $ 876 K usaUSA
BioLineRx Ltd. BioLineRx Ltd.
BLRX
$ 3.13 -0.87 % $ 908 M israelIsrael
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
- - $ 7.46 M israelIsrael